BRAF L485-P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review.

导出 LinkOut

翻译打印收藏纠错

作者： Simeng,Zhang ^[1] ; Zichang,Yang ^[2] ; Yu,Cheng ^[3] ; Xiaoyu,Guo ^[1] ; Chang,Liu ^[2] ; Shuo,Wang ^[3] ; Lingyun,Zhang ^[1]

作者单位： Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China. ^[1] Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China. ^[2] Liaoning Province Clinical Research Center for Cancer, Shenyang, China. ^[3]

关键词 BRAF in-frame deletion mutation case report dabrafenib metastatic melanoma trametinib

DOI 10.3389/fphar.2022.1019217

PMID 36686670

发布时间 2023-02-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in pharmacology

2022年13卷

1019217页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

BRAF L485-P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

BRAF L485-P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

检索历史清除